Clinical Characteristics on Admission Predict In-Hospital Fatal Outcome in Patients Aged ≥75 Years with novel coronavirus disease (COVID-19): A Retrospective Cohort Study

Zhihua Yu  
Capital Medical University Affiliated Anzhen Hospital

Yuhe Ke  
First Hospital of Wuhan City

Jiang Xie  
Capital Medical University Affiliated Anzhen Hospital

Hao Yu  
First Hospital of Wuhan City

Wei Zhu  
First Hospital of Wuhan City

Liqun He  
First Hospital of Wuhan City

Qiongli Zheng  
First Hospital of Wuhan City

Chuanwei Li  
Third Military Medical University Daping Hospital and Research Institute of Surgery

Jingya Lu  
Huazhong University of Science and Technology Tongji Medical College

Songnan Li  
Capital Medical University Affiliated Anzhen Hospital

Songnan Wen  
Capital Medical University Affiliated Anzhen Hospital

Sheng Wei  
Huazhong University of Science and Technology Tongji Medical College

Nian Liu  
Capital Medical University Affiliated Anzhen Hospital

Li Wei  
First Hospital of Wuhan City

Rong Bai  
Capital Medical University Affiliated Anzhen Hospital  
rbairong74@gmail.com  
https://orcid.org/0000-0002-3106-7318

Research article

Keywords: Coronavirus disease, SARS-CoV-2, elderly, death, prediction

DOI: https://doi.org/10.21203/rs.3.rs-36077/v3

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Novel coronavirus disease COVID-19 has become a worldwide pandemic and precise fatality data by age group are needed urgently. This study to delineate the clinical characteristics and outcome of COVID-19 patients aged ≥75 years and identify the risk factors of in-hospital death.

Methods: A total of 141 consecutive patients aged ≥75 years who were admitted to the hospital between 12th and 19th February 2020. In-hospital death, clinical characteristics and laboratory findings on admission were obtained from medical records. The final follow-up observation was 31st March 2020.

Results: The median age was 81 years (84 female, 59.6%). Thirty-eight (27%) patients were classified as severe or critical cases. 18 (12.8%) patients had died in hospital and the remaining 123 were discharged. Patients who died were more likely to present with fever (38.9% vs. 7.3%); low percutaneous oxygen saturation (SpO2) (55.6% vs. 7.3%); reduced lymphocytes (72.2% vs. 35.8%) and platelets (27.8% vs. 4.1%); and increased D-dimer (94.4% vs. 42.3%), creatinine (50.0% vs. 22.0%), lactic dehydrogenase (LDH) (77.8% vs. 30.1%), high sensitivity troponin I (hs-TnI) (72.2% vs. 14.6%), and N-terminal pro-brain natriuretic peptide (NT-proBNP) (72.2% vs. 6.5%); all P<0.05 than patients who recovered. Male sex (odds ratio [OR]=13.1, 95% confidence interval[CI] 1.1 to 160.1, P=0.044), body temperature >37.3°C (OR=80.5, 95% CI 4.6 to 1407.6, P=0.003), SpO2 ≤ 90% (OR=70.1, 95% CI 4.6 to 1060.4, P=0.002), and NT-proBNP>1800ng/L (OR=273.5, 95% CI 14.7 to 5104.8, P<0.0001) were independent risk factors of in-hospital death.

Conclusions: In-hospital fatality among COVID-19 patients can be estimated by sex and on-admission measurements of body temperature, SpO2, and NT-proBNP.

Background

In December 2019, Wuhan city, the capital of Hubei province in China, became the centre of an outbreak of pneumonia caused by a novel coronavirus, which was designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the World Health Organization (WHO) [1-3]. The disease was then named coronavirus disease 2019 (COVID-19) [4] and was classified as a global pandemic in March 2020 [5].

The clinical presentation of COVID-19 varies from asymptomatic to mild flu-like symptoms to acute respiratory distress syndrome (ARDS). Other symptoms include neurological manifestations, such as confusion, impaired consciousness [6]; abnormalities associated with acute myocardial injury and heart failure [7]. These symptoms are more common in the elderly. As of September 2020, the overall mortality of COVID-19 was 3.2% globally and 5.2% in China [8]. However, mortality in the elderly (≥60 years) was consistently reported as high as 20% [9,10] from different centers worldwide, suggesting that advanced age is associated with increased mortality and case fatality rate. Kremer S et al [6] showed that COVID-19 patients had more neurological symptoms. Neurological complications including stroke and encephalopathy have been seen in other elderly COVID-19 populations which was associated with greater morbidity and increased social and economic burden. The study by Liu et al [11] specifically compared the outcome of older COVID-19 patients with individuals at younger age and also found that mortality of elderly patients with COVID-19 was higher; however, their study included a very small sample size and did not identify any risk factor. Therefore, we aimed to investigate the clinical characteristics of COVID-19 patients aged ≥75 years and to identify risk factors that may predict in-hospital death.

Methods

Study design and participants

This was retrospective cohort study enrolling consecutive COVID-19 patients who were admitted to the First Hospital of Wuhan. This institution is one of the major tertiary teaching hospitals of Wuhan city and was selected as a COVID-19 designated hospital by the government on 11th February 2020. From 12th February 2020, by regulation the hospital only admitted confirmed COVID-19 patients who were in moderate, severe, or critical condition (defined below). Patients were 1) transferred from other non-designated hospitals, 2) transferred from the cabin hospitals because he/she progressed from a mild case to the stage of moderate or above and needed intensive care, or 3) directly admitted from the fever clinic of the First Hospital of Wuhan.

This study was approved by the Institutional Ethics Board of the First Hospital of Wuhan (No.202008) on February 12, 2020. Given the limited availability of human resource during the initial sweep of the pandemic, written consent was waived in the aforementioned ethic approval and thus oral consent was obtained from each patient to use his/her medical records for research purposes.

Diagnosis criteria
All patients with COVID-19 enrolled in this study were diagnosed according to the WHO interim guidance [12] and the contemporary “Protocols for the Diagnosis and Treatment of 2019 New Coronavirus Pneumonia” issued by the National Health Commission of the People’s Republic of China [13]. In addition to clinical and lung imaging manifestations, all confirmed COVID-19 cases required at least one positive test result of the pathogen, i.e. the nucleic acid of the SARS-CoV-2 virus. Classification of mild, moderate, severe, or critical case was made using the following criteria[13]:

1. Mild: clinical symptoms are mild and no pneumonia manifestations can be found on lung imaging.
2. Moderate: symptomatic and typical ground-glass opacity lesions on lung imaging.
3. Severe: presenting with any of the following: respiratory rate of ≥30 breaths/min; oxygen saturation ≤93% at rest, arterial partial pressure of oxygen (PaO2)/oxygen concentration (FiO2) of ≤300mmHg, >50% lesion progression within 24-48h.
4. Critical: meeting any of the following: respiratory failure requiring mechanical ventilation, presence of shock, extra-pulmonary organ failure.

**Treatment and discharge**

In general, the management of COVID-19 patients followed the National's protocol [13] and included antiviral treatment, anti-hypoxemia treatment, prevention of complications, and supportive care. Specific therapy was determined at the attending physician's discretion. Approved by a multi-disciplinary specialist team, a COVID-19 patient could be discharged from hospital if he/she remained within the range of normal body temperature for at least 3 days, exhibited significant improvement in respiratory symptoms, had an SpO2>93% without oxygen inhalation, tested negative for SARS-CoV-2 nucleic acid twice consecutively (sampling>24h apart), exhibited significant improvement in lesions on lung computed tomography (CT), and had no other comorbidities or complications that required hospitalization.

**Clinical data collection and laboratory procedures**

The electronic medical records of the patients were reviewed. Recorded information included demographic data, medical history, epidemiological history, underlying comorbidities, symptoms, signs, laboratory findings, radiological characteristics, and treatment. The date of disease onset was defined as the day when the symptom was first noticed. The last follow-up observation was 31st March 2020; by this date, all patients included in the present study were either deceased or had been discharged from hospital.

Laboratory confirmation of SARS-CoV-2 infection by real-time reverse-transcription polymerase chain reaction assay has been described elsewhere [14]. Briefly, throat swab samples were collected, and the total RNA was extracted within 2h using the RNA Isolation Kit (Jiangsu Bioperfectus Technologies, Taizhou, China). Two target genes, including open reading frame lab (ORF lab) and nucleocapsid protein (N), were simultaneously amplified and tested.

Routine blood tests were conducted at the central laboratory of the hospital. These included a complete blood count, serum biochemical markers, electrolytes, myocardial enzymes, N-terminal pro-brain natriuretic peptide (NT-proBNP), D-dimer, C reaction protein (CRP), and procalcitonin (PCT). All patients underwent a chest CT scan immediately on admission to evaluate the presence of lung lesions and an electrocardiogram. Examinations were repeated as needed during hospitalization.

**Statistical analysis**

Categorical variables were described as frequencies and percentages, and continuous variables were described using median and interquartile range (IQR) values. The primary endpoint of our study was the in-hospital outcome, according to which all the patients were divided into two groups: “Death” and “Discharged.” We used the Mann-Whitney U test, χ² test, or Fisher's exact test to compare the differences in variables between the two groups where appropriate. Univariate and multivariate non-conditional logistic regression models were used to explore the risk factors associated with in-hospital death. Clinical presentations and laboratory measurements that reported as continuous variable were categorised into binary data using the cut-off value of the normal range recommended by the central laboratory (Supplementary Table Reference range of laboratory values in the Additional file 1). All demographic, clinical, and laboratory data that exhibited significant or borderline significant differences both in continuous and categorical data comparison between the two groups were first tested in the univariate model. and then entered into the multivariate model if they achieved statistical significance (P<0.1) in the univariate analysis. Logistic regression was used to develop a predictive model to the primary endpoint, of which the performance was justified by the area under the curve (AUC) of the ROC. The Z test was used to compare the performance of multiple models. All statistical analyses were performed using SPSS (version 24.0, SPSS Inc.) and MedCalc (version 19.1) software. A P-value of <0.05 was considered statistically significant.
Patient and public involvement reporting

This was a retrospective cohort study, and no patients were involved in the study design or in setting the research questions or the outcome measures directly. No patients were asked to advise on interpretation or writing up of results.

Study results will be summarized and released by professional social media and presented at relevant conferences after publication. The STONP prediction model will be shared for free by means of online tool and App.

Results

Patient demographic characteristics

Between 12th February and 19th February 2020, 1,077 adult COVID-19 patients were admitted to the First Hospital of Wuhan; among them, 141 (13.1%) consecutive patients aged ≥75 years were included in the present study. The median age was 81 years (IQR,78-85), ranging from 75 to 97 years, and the majority were female (84, 59.6%). The median time from disease onset to hospitalization was 10 (IQR, 6.0-14.5)days.

Comorbidities were present in 76.6% of patients, with cardiovascular diseases including hypertension, coronary heart disease, and atrial fibrillation being the most common comorbidity (63.1%). Other comorbidities included endocrine disorders (25.5%, including diabetes, thyroid dysfunction), central nerve system disorders (21.3%, including stroke, Alzheimer’s disease, and Parkinson’s disease), respiratory diseases (15.6%, including chronic obstructive pulmonary disease, asthma and tuberculosis), chronic kidney disease (3.5%), and malignancy (5.7%). Epidemic investigation indicated that no patient had a history of direct contact with Huanan seafood market in Wuhan city.

Patient outcome

Overall, 18 patients died (Death group) during hospitalization, corresponding to an in-hospital fatality rate of 12.8%. The cause of death was refractory shock in eight patients and acute respiratory distress syndrome (ARDS) in ten patients (sustained hypoxia despite of ventilation in five patients). By 31st March 2020, the remaining 123 patients had been discharged (Discharged group) from hospital after proper treatment. The median time from admission to discharge was 29(IQR, 25.0-36.0) days and from illness onset to death or discharge was 39.0(IQR, 31.0-48.0) days. The latter was significantly shorter in the Death group (26.5, IQR 14.8-38.8 days vs. 40.0, IQR 33.0-50.0 days in the Discharged group, P<0.0001).

The age-stratified fatality rate is provided in Figure 1 with the highest fatality rate at 27.3% in the ≥90 years subgroup. Although there seemed a trend of an increase of fatality rate by age, the comparison across all age subgroups did not achieve statistical significance ($\chi^2=5.259;P=0.154$).

Clinical presentations and laboratory tests on admission

The majority of patients (64.5%) reported being febrile since the onset of disease but only 11.3% of the population had fever (defined as an axillary temperature of >37.3°C) on arrival. Other common symptoms on admission were dry cough (53.9%), fatigue (39.0%), and expectoration (35.5%) as listed in Table 1. The incidence of all symptoms was comparable between the Death and the Discharged groups.

Table 1 Clinical Characteristics on Admission of Patients in the Discharged and Death Groups

Some patients presented with signs suggesting unstable condition including heart rate of >100bpm (9.9%), respiratory rate of >24 breaths/min (11.3%), systolic blood pressure of ≤90mmHg (1.4%), and SpO$_2$≤90% on room air (13.5%). When comparing between groups, there were significantly more patients in the Death group with these signs on admission (Table 1).

The laboratory test results on admission were summarized in Table 2. In the Death group, there was a markedly higher percentage of patients with abnormal findings in terms of the white blood cell count, lymphocyte count, neutrophil count, platelet count, CRP, PCT, D-dimer, blood urea nitrogen, creatinine, lactic dehydrogenase (LDH), N-terminal pro-brain natriuretic peptide (NT-proBNP), and hypersensitive troponin I hs-TnlI. All patients underwent a CT scan immediately before or after they were admitted to hospital; 37.6% had typical ground-glass opacity lesions in at least three lung lobes.

Table 2 Laboratory Findings on Admission in the Discharged and Death Groups

Overall, 38 patients (27%) were classified as severe or critical cases on admission and required immediate intensive care. These patients accounted for 77.8% of all cases of in-hospital death. This ratio was markedly higher than that in the Discharged group (24 severe/critical
cases on admission of 123 discharged patients, 19.5%, P<0.0001).

Complications and treatment during hospitalization

After admission, 27.7% of the patients developed de novo arrhythmias including atrial fibrillation with rapid ventricular response, atrial flutter, atrial tachycardia, and first- or second-degree heart block, but no life-threatening arrhythmia was observed in our population. The incidence of arrhythmic occurrence in two groups was similar. Of the 123 patients who were eventually discharged, only seven (5.7%) deteriorated to ARDS during hospitalization, while in the Death group, this incidence was 55.6% (P<0.0001). Deterioration to refractory shock was seen in eight patients who all died.

Arbidol was the most frequently (91.5%) used antiviral medicine. Most patients received antibiotics (76.6%), while 20.6% received glucocorticoid therapy. Mechanical ventilation, either non-invasive or invasive (IMV), was required in 21 cases (14.9%); six of these patients were intubated (IMV). Other treatments for COVID-19 are detailed in Table 3. Patients who received antibiotics, antifungal agents, or glucocorticoids; who needed immunoglobulin or blood transfusion; and who required mechanical ventilation were more likely to have a fatal outcome.

Table 3 Complication and Treatment during hospitalization in the Discharged and Death Groups

Risk factors of in-hospital death

We tested the demographic and laboratory variables that exhibited a borderline significant or significant difference between the Discharged and Death groups in the univariate regression analysis, with the exception of age and CRP. Because there was collinearity between the variables of WBC, lymphocyte, and neutrophil, we excluded WBC and neutrophil. So totally 16 variables were included in the multivariate regression. The results indicated that male sex (odds ratio [OR]=13.1, 95% confidence interval [CI]1.1 to 160.1, P=0.044) and three on-admission check-ups including body temperature of >37.3°C (OR=80.5, 95% CI 4.6 to 1407.6, P=0.003), SpO2 of ≤90% without additional oxygen supply (OR=70.1, 95% CI 4.6 to 1060.4, P=0.002), and NT-proBNP of >1800ng/L (OR=273.5, 95% CI 14.7 to 5104.8, P<0.0001) were independent risk factors of fatal outcome.

To predict in-hospital death for elderly COVID-19 patients, a statistical model, namely Sex, Temperature, SpO2, and NT-proBNP (STONP), was developed using logistic regression and then the ROC curve was plotted. In the present derivation cohort, the AUC of the STONP model was 0.971 (95% CI 0.928 to 0.992) with a negative predictive value of 98.4% and a positive predictive value of 77.8%. As a validation cohort was unavailable at this time, we compared the STONP model with the Mortality Probability Models II-Admission (MPM-II Adm), which has been widely used in intensive care medicine to calculate the possibility of in-hospital death. The performance of the STONP model was comparable with that of the MPM-II Adm (AUC 0.915, 95% CI 0.856 to 0.955; z statistic 1.814, P=0.0697 vs. STONP; Figure 2). A web-based tool and an App (Android system only) of the STONP model are available at this hyperlink: https://janzhou.org/covid-19/stonp.html or via the barcodes provided in the Additional file 1.

Table 4 Univariate and Multivariate Logistic Regression for Prediction of In-hospital Death

Discussion

Our study summarized the clinical characteristics and explored the risk factors of in-hospital death of elderly COVID-19 patients. We found that the overall fatality rate of COVID-19 patients aged ≥75 years was 12.8%; over >25% of patients presented as severe or critical cases on admission and required intensive care; and patients who were male and presented with a body temperature >37.3°C, SpO2≤90%, and NT-proBNP>1800ng/L were at high risk of death. The STONP model including these four risk factors performed well in predicting in-hospital death.

Most of the published studies [6,7,11,14] on COVID-19 were cross-sectional analysis with no follow-up. All patients in our study were admitted to hospital and reached an endpoint of either death or discharge. Further, unlike the data reported in studies during the early phase of the pandemic in Wuhan [10,14] our data in the late phase when medial overwhelming had been resolved reflect the real-world outcome of elderly COVID-19 patients. Although it is well established that the risk of death from COVID-19 increases with older age [15,16], the reported mortality rates in other studies were either retrieved from a general COVID-19 population or adjusted using statistical models [17,18]. When the fatality rates are highly variable across age groups, it is critical to obtain data from age-specific cohort. Our study in patients ≥75 years served a timely response to the call by R. Bhopal [19] who emphasized the urgent need of precise data on COVID-19 by age group. We found that the overall fatality rate in elderly COVID-19 patients was 12.8%, but this rate did not significantly differ among septuagenarians, octogenarians, and nonagenarians. Our result is of unique importance to the aging countries.
Although elderly people might be most vulnerable to SARS-CoV-2 infection, elderly patients are not necessarily always severe or critical cases. On admission, 37.6% of our patients had lesions in at least three lung lobes, but the fatality rate (12.8%) was <50% of this rate. It seems that the variable prognosis of COVID-19 patients was determined by the underlying health condition. Comorbidities were present in 76.6% of our patients. Previous studies [20] reported similar findings that non-survivors presented higher proportion of various co-existing chronic illness. The immunosenescence and malnutrition could lead to a deficiency in control of viral replication. The elderly are more prone to an uncontrolled activation of innate immune response that leads to cytokine release syndrome and tissue damage [21]. Nutritional deficits are most prevalent in older population, thus contributing to weakening of the immune system [22]. As indicated in our results, the median time from symptom onset to admission was shorter in deceased patients (7 days) than in patients who recovered (10 days), suggesting that rapid disease progression during the initial phase could be a sign of a poorer outcome. In contrast, the percentage of patients who were febrile (64.5%) or had a fever on admission (11.3%) was markedly lower than that reported in the general adult COVID-19 population (94% and 43.8%, respectively) [15,23]. An elderly patient could be too weak to have the body temperature raised, which is actually a warning sign of serious condition. We also found that females accounted for the majority of cases in this elderly cohort, but male sex was a risk factor of in-hospital death. One possible explanation is that females generally have a longer life span than males, while Asian men have five-fold more ACE2-expressing cells [24], the target of the SARS-CoV-2 virus, in the lungs than Caucasians or females. However, if this was the case, male sex could lose its predictive power in patients of other ethnicities. Future studies should validate the STONP model in different ethnicities.

Thus far, there is no specific treatment for COVID-19 [25]. The empirical use of anti-viral agents does not seem to be associated with better outcome. Further, it is controversial to administer steroids in cases of viral pneumonia including COVID-19 [26-30]. In our cohort, glucocorticoid administration was not common (20% of cases), likely due to concerns of advanced age. Approximately 50% of these cases died accounting for >70% of the deceased cases. Over 75% of patients were administered antibiotics, including all 18 deceased cases. Nevertheless, these results did not indicate that steroid or antibiotic use was a determinant of fatality in elderly COVID-19 patients.

One of the risk factors identified in our study was a body temperature of >37.3°C on admission. The fact that the median time from disease onset to hospitalization was 7 days in the Death group suggested that sustained fever was indicative of a poor outcome. We also identified NT-proBNP of >1800ng/L as a risk factor of death. This cut-off value had been adjusted for age and renal function. Although BNP is a sensitive marker of heart failure, it is a prognostic parameter in chronic lung disease and its secretion increases in pulmonary congestion of any reason [31], which is present after significant exudation in the lungs of COVID-19 patients [32]. Meanwhile, a higher NT-proBNP level could be a result of myocardial injury, which was observed in >20% of our patients.

We believe that the four independent risk factors of in-hospital death identified in our elderly COVID-19 population reflected the patients’ vulnerability to the virus (male sex), progression of the disease (temperature on admission), severity of lung lesions (SpO₂ on room air, NT-proBNP), and function of other organs (NT-proBNP). Based on this finding, we developed the STONP model with the aim of rapidly detecting patients at high risk of death upon admission with minimum measurements. The performance of the STONP model was comparable to that of the MPM-II Adm which was designed to use a series of signs and measurements on admission to predict the probability of death [33]. This model, consisting of 15 parameters, has been validated in >10,000 cases [34] including those with similar conditions as COVID-19. It seems that our STONP model specifically established for elderly COVID-19 patients is simpler and easier to use than the MPM-II Adm. In addition, there are other models that have been established to predict death or organ failure in patients in intensive condition including the quick Sequential Organ Failure Assessment (qSOFA) score [35]. The qSOFA allows identifying patients with suspected infection who are at greater risk for a poor outcome outside the intensive care unit (ICU) which theoretically applies to COVID-19 patients. In comparison with MPM-II Adm and our STONP model, the qSOFA scale uses 3 clinical variables without any laboratory parameters. It is known for convenient, bedside use but the selected clinical variables (low blood pressure SBP≤100 mmHg, high respiratory rate ≥22 breaths per min, altered mentation Glasgow coma scale<15) were too general to reflect the features of any specific disease. Although not directly compared in our study, one could expect a very low sensitivity of the qSOFA performance in COVID-19 population.

Our study has some notable limitations. First, this study reflected experience from single centre, single country with a relatively small sample size. Second, it specifically addressed the characteristics of elderly COVID-19 patients; therefore, the results may not apply to younger patients. Third, we did not acquire data on patients’ status after discharge. Finally, the STONP model was not validated in an external cohort. Investigators from around the world may use the free access to the STONP model and validate it in different population.

Conclusions

In this age-stratified cohort, we found that the overall case fatality rate of COVID-19 patients aged ≥75 was 12.8% and this rate was similar among septuagenarians, octogenarians, and nonagenarians. The STONP model, consisting of sex and simple on-admission measurements including body temperature, SpO₂, and NT-proBNP, can aid the early detection of elderly COVID-19 patients at high risk of in-hospital death.
Abbreviations

ARDS: acute respiratory distress syndrome; ACE2: angiotensin-converting enzyme 2; ALT: alanineaminotransferase; AST: aspartateaminotransferase; BUN: blood urea nitrogen; CK-MB: creatine kinase-MB; COVID-19: coronavirus Disease 2019; CK: creatine kinase; CT: computed tomography; CRP: C-reactive protein; Hs-TnI: hypersensitive troponin I; LDH: lactic dehydrogenase; NT-proBNP: N-terminal pro-brain natriuretic peptide; RBC: red blood cell; RNA: ribonucleic acid; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; SBP: systolic blood pressure; SpO2: arterial partial pressure of oxygen; TB: total bilirubin; WBC: white blood cell.

Declaration

Ethics approval and consent to participate

This study was approved by the Institutional Ethics Board of the First Hospital of Wuhan (No.202008). Oral consent was obtained from each patient to use his/her medical records for research purposes. The need to obtain written consent was waived by the Ethics Board for emerging infectious diseases.

Consent for publication

Not applicable.

Availability of data and materials

Data are stored by First Hospital of Wuhan City on servers with security according to the rules given by Chinese law. The data can be made available by reasonable request to the corresponding author.

Competing interests

Zhihua Yu, Yuhe Ke, Jiang Xie, Hao Yu, Wei Zhu, Liqun He, Qiongli Zheng, Chuanwei Li, Jingya Lu, Songnan Li, Songnan Wen, Sheng Wei, Nian Liu and Rong Bai declared that there were no competing interests. Li Wei is the recipient of grants from the National Administration of Traditional Chinese Medicine Special Scientific Research Fund for COVID-19.

Funding

This work was partially supported by the National Administration of Traditional Chinese Medicine (2020ZYLCYJ03-11). The research was designed, conducted, analysed, and interpreted by the authors entirely independently of the funding sources.

Author's Contribution

ZY, RB, NL and YK put forward the concept and designed the study. ZY, YK, JX, HY, WZ, LH, CL and QZ collected the epidemiological and clinical data. ZY, JX, HY, WZ, SL, S-N W, SW, NL and JL analyzed or interpreted the data. ZY, LJ, SW and RB made statistical analysis. RB, ZY drafted the manuscript. YK, HY, JL, SW, WZ and LW provided administrative, technical, or material support. JX, SL, SW, LH, CL, QZ, LW and NL critically revised the manuscript for important intellectual content. All authors have read and approved the manuscript.

Acknowledgments

We would like to thank all our patients involved in this study and their families, as well as all our colleagues and civilians of Wuhan city working together to win the battle against COVID-19.

Author details

1Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China; 2Department of Cardiology, First Hospital of Wuhan City, Wuhan 430022, China; 3Department of Respiratory and Critical Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China; 4Department of Cardiology, Daping Hospital, Third Military Medical University, Chongqing 400042, China; 5Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; 6Beijing Institute of Heart, Lung & Blood Vessel Diseases, Beijing 100029, China; 7National Clinical Research Center of Cardiovascular Diseases, Beijing 100029, China

References
1. Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China: challenges for global health governance. JAMA. 2020; 323: 709-10.

2. Alexander EG, Susan CB, Ralph SB, Raoul JG, Christian D, Anastasia AG, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020; 5: 536-44.

3. Chan JW M, Ng CK, Chan YH, Mok TY W, WHO, Lee S, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax. 2003; 58: 686-9.

4. World Health Organization: Naming the coronavirus disease (COVID-19) and the virus that causes it. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it(2020). Accessed 16 April 2020.

5. World Health Organization: characterizes COVID-19 as a pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen(2020). Accessed 16 April 2020.

6. Kremer S, Lersy F, Anheim M, Merdji H, Schenck M, Oesterlé H, et al. Neurologic and neuroimaging ndings in COVID-19 patients: A retrospective multicenter study. Neurology. 2020. doi: 10.1212/WNL.0000000000010112.

7. Wei CC, Liu Y, Liu YP, Zhang K, Su DZ, Zhong M, et al. Clinical characteristics and manifestations in older patients with COVID-19. BMC Geriatrics. 2020;20:395-404.

8. World Health Organization: COVID-19 situation reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports(2020). Accessed 13 Sept 2020.

9. Agnieszka NP, Salwan RA, Lukasz MK, Michal C, Slawomir T, Katarzyna W. COVID 19-Clinical Picture in the Elderly Population: A Qualitative Systematic Review. Aging and Disease. 2020; 11: 988-1008.

10. Wang L, He Wb, Yu Xm, Hu Di, Bao Mw, Liu Hf, et al. Coronavirus diseases 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. Journal of Infection. 2020; 80: 639-45.

11. Liu K, Chen Y, Lin Rz, Han Ky. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. Journal of Infection. 2020; 80: e14-8.

12. World Health Organization: Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected(2020). Accessed 16 April 2020.

13. National Health Commission of the People's Republic of China: Protocols for the diagnosis and treatment of 2019 new coronavirus pneumonia. 6th http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfcb1bc54639af227f922bf6b817.pdf (2020). Accessed 16 April 2020.

14. Chen T, Wu D, Chen HL, Yan WM, Yang DL, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020. doi:1136/bmj.m1091.

15. Zhou F, Yu T, Du RH, Fan GH, Liu Y, Liu ZB, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet . 2020. doi:10.1016/S0140-6736(20)30566-3.

16. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA.2020. doi:10.1001/jama.2020.2648.

17. Raj Bhopal. Covid-19 worldwide: we need precise data by age group and sex urgently. BMJ. 2020; 369: m1366. doi:10.1136/bmj.m1366.

18. Chen RC, Liang WH, Jiang M, Guan WJ, Zhan C, Wang T, et al. Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China. Chest. 2020;158:97-105.

19. Cunha LL, Perazzio SF, Azzi J, Cravedi P, Riella LV. Remodeling of the Immune Response With Aging: Immunosenescence and Its Potential Impact on COVID-19 Immune Response. Frontiers in Immunology. 2020. doi:10.3389/fimmu.2020.0174.

20. Bencivenga L, Rengo G, Varricchi G. Elderly at time of Corona Virus disease 2019(COVID-19): possible role of immunosenescence and malnutrition. GeroScience. 2020;42:1089-92.

21. Guan W, Ni Z, Hu Y, Liang W, OU C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New Engl J Med. 2020;382:1708-20.
24. Zhao Y, Zhao ZX, Wang YJ, Zhou YQ, Ma Y, Zou W. Single-cell RNA Expression Profiling of ACE2, The Receptor of SARS-CoV-2. Am J Respir Crit Care Med. 2020. doi: 10.1164/rccm.202001-0179LE.

25. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020. doi:10.1001/jama.2020.6019.

26. Bencivenga L, Rengo G, Varricchi G. Elderly at time of COVID-19: possible role of immunosenescence and malnutrition. Geroscience. 2020;42:1089-92.

27. Zhang W, Zhao Y, Zhang FC, Wang Q, Li TS, Liu ZY, et al. Anti-inflammation treatment of severe coronavirus disease 2019 (COVID-19): from the perspective of clinical immunologists from China. Clinical Immunology. doi:10.1016/j.clim.2020.108393.

28. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3: e343.

29. Louise EL, Chamira R, Jo LB, Jonathan NVT, Wei SL. Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis. Critical Care Medicine. 2019;48:1.

30. Yaseen MA, Yasser M, Fahad AH, Anees AS, Ghaleb AA, Mohamed AH, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med.2018, 197: 757-767.

31. Hanno HL, Rainer AB, Michal EN, Michael V, Claus N, Michael T, et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med. 2006;173: 744-750.

32. Xu Z, Shi L, Wang YJ, Zhang JY, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020. doi:10.1016/S2213-2600(20)30076-X.

33. Lemeshow S, Teres D, Klar J, Avrunin JS, Gehlbach SH, Rapoport J. Mortality Probability Models (MPM II) Based on an International Cohort of Intensive Care Unit Patients. JAMA. 1993;270: 2478-2486.

34. Lemeshow S, Le Gall JR. Modeling the severity of illness of ICU patients. A systems update. JAMA. 1994;272: 1049-1055.

35. Seymour CW, Liu VX, Iwashyna TJ, Brunhkhorst FM, Rea TD, Scherag A, et al. Assessment of Clinical Criteria for Sepsis: For the third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:762-74

Tables

Table 1 Clinical Characteristics on Admission of Patients in the Discharged and Death Groups
|                                | Total (n=141) | Discharged (n=123) | Death (n=18) | P value |
|--------------------------------|---------------|-------------------|--------------|---------|
| Median age(IQR)-years          | 81.0(78.0-85.0) | 80.0(77.0-85.0)   | 83.5(80.8-86.3) | 0.019   |
| Sex-no. (%)                    |               |                   |              |         |
| Male                           | 57(40.4)      | 46(37.4)          | 11(61.1)     | 0.056   |
| Female                         | 84(59.6)      | 77(62.6)          | 7(38.9)      |         |
| Severe / Critical case-no. (%) | 38(27.0)      | 24(19.5)          | 14(77.8)     | 0.000   |
| Days from illness onset to admission-median days(IQR) | 10.0(6.0-14.5) | 10.0(6.0-15.0) | 7.0(5.0-10.0) | 0.069   |
| Comorbidity-no. (%)            |               |                   |              |         |
| Cardiovascular diseases        | 89(63.1)      | 76(61.8)          | 13(72.2)     | 0.391   |
| Endocrine disorders            | 36(25.5)      | 30(24.4)          | 6(33.3)      | 0.601   |
| Central nerve system disorders | 30(21.3)      | 20(16.3)          | 10(55.6)     | 0.000   |
| Respiratory diseases           | 22(15.6)      | 19(15.4)          | 3(16.7)      | 1.000   |
| Malignancy                     | 8(5.7)        | 7(5.7)            | 1(5.6)       | 1.000   |
| Chronic kidney disease         | 5(3.5)        | 1(0.8)            | 4(22.2)      | 0.001   |
| Symptom, no. (%)               |               |                   |              |         |
| Fever                          | 91(64.5)      | 79(64.2)          | 12(66.7)     | 0.840   |
| Dry cough                      | 76(53.9)      | 69(56.1)          | 7(38.9)      | 0.171   |
| Fatigue                        | 55(39.0)      | 50(40.7)          | 5(27.8)      | 0.296   |
| Expectoration                  | 50(35.5)      | 43(35.0)          | 7(38.9)      | 0.745   |
| Dyspnea                        | 46(32.6)      | 37(30.1)          | 9(50.0)      | 0.092   |
| Anorexia                       | 42(29.8)      | 37(30.1)          | 5(27.8)      | 0.842   |
| Myalgia                        | 12(8.5)       | 10(8.1)           | 2(11.1)      | 1.000   |
| Nasal congestion               | 9(6.4)        | 9(7.3)            | 0(0)         | 0.503   |
| Lethargy                       | 9(6.4)        | 7(5.7)            | 2(11.1)      | 0.717   |
| Pharyngalgia                   | 6(4.3)        | 5(4.1)            | 1(5.6)       | 0.566   |
| Diarrhea                       | 6(4.3)        | 6(4.9)            | 0(0)         | 1.000   |
| Dizziness                      | 5(3.5)        | 3(2.4)            | 2(11.1)      | 0.122   |
| Nausea                         | 4(2.8)        | 4(3.3)            | 0(0)         | 1.000   |
| Headache                       | 4(2.8)        | 3(2.4)            | 1(5.6)       | 0.425   |
| Vomiting                       | 4(2.8)        | 4(3.3)            | 0(0)         | 1.000   |
| Sign                           |               |                   |              |         |
| Temperature,median (IQR)-°C    |               |                   |              |         |
| >37.3-no. (%)                  | 36.5(36.3-36.8)| 36.5(36.2-36.8)  | 36.8(36.5-37.9)| 0.003   |
| HR, median (IQR)-bpm           |               |                   |              |         |
| >100-no. (%)                   | 84.0(76.0-93.5)| 84.0(76.0-92.0)  | 86.5(75.0-96.5)| 0.542   |
| RR, median (IQR)-bpm           | 14(9.9)       | 13(10.6)          | 1(5.6)       | 0.808   |
| >24-no. (%)                    | 20.0(19.0-22.0)| 20.0(19.0-22.0)  | 22.0(19.8-25.0)| 0.027   |
| SBP, median (IQR)-mmHg         |               |                   |              |         |
| ≤90-no. (%)                    | 133.0(123.5-146.5)| 135.0(125.0-148.0)| 126.5(119.3-139.0)| 0.093   |
| ≤90%-%-no. (%)                 | 96.0(93.0-98.0)| 97.0(95.0-98.0)  | 89.5(84.8-93.8)| 0.000   |

*P* values denoted the comparison between Discharged and Death groups. Cardiovascular diseases included hypertension, coronary heart disease and atrial fibrillation; Endocrine disorders included diabetes mellitus and hypothyroidism; Central nerve system disorders included stroke, Alzheimer’s disease, and Parkinson’s disease; Respiratory diseases included chronic obstructive pulmonary disease, asthma and tuberculosis. *bpm* beats per minute or breath per minute, *HR* heart rate, *RR* respiratory rate, *SBP* systolic blood pressure, *SpO₂* pulse oxygen saturation, *IQR* interquartile range.

**Table 2** Laboratory Findings on Admission in the Discharged and Death Groups
|                          | Total (n=141) | Discharged (n=123) | Death (n=18) | P value |
|--------------------------|---------------|-------------------|--------------|---------|
| WBC×10⁹/L, median (IQR) |               |                   |              |         |
| >10-no. (%)              | 18(12.8)      | 10(8.1)           | 8(44.4)      | 0.000   |
| ≤1.1-no. (%)             | 57(40.4)      | 44(35.8)          | 13(72.2)     | 0.003   |
| Neutrophil×10⁹/L, median (IQR) |            |                   |              |         |
| >6.3-no. (%)             | 4.0(24.1)     | 3.9(24.1)         | 7.2(10.5)    | 0.002   |
| ≤100-no. (%)             | 225.0(163.5-296.0) | 234.0(172.0-301.0) | 134(96.5-217.0) | 0.001   |
| RBC×10¹²/L, median (IQR) |               |                   |              |         |
| >10-no. (%)              | 3.9(3.6-4.3)  | 3.9(3.6-4.3)      | 3.7(3.0-4.0) | 0.023   |
| ≤110-no. (%)             | 120.0(109.5-130.0) | 121.0(111.0-131.0) | 112.0(100.0-119.0) | 0.009   |
| CRP-mg/L, median (IQR)   |               |                   |              |         |
| >5.0-no. (%)             | 13.2(3.2-39.1) | 9.0(3.1-28.8)     | 106.0(21.9-150.0) | 0.000   |
| Procalcitonin-ng/L, median (IQR) |      |                   |              |         |
| >500-no. (%)             | 40.0(20.0-100.0) | 40.0(20.0-70.0)   | 360.0(97.5-1235.0) | 0.000   |
| D-dimer-ng/L, median (IQR) |             |                   |              |         |
| >1.0-no. (%)             | 0.9(0.8-3.4)  | 0.9(0.8-2.7)      | 3.1(2.1-12.1) | 0.000   |
| Creatinine-μmol/L, median (IQR) |         |                   |              |         |
| >97-no. (%)              | 69.0(58.0-98.0) | 68.0(57.0-94.0)   | 96.0(64.3-133.3) | 0.026   |
| BUN-mmol/L, median (IQR) |               |                   |              |         |
| >7.1-no. (%)             | 6.3(4.4-8.3)  | 5.4(4.1-7.5)      | 9.8(6.8-13.6) | 0.000   |
| AST-IU/L, median (IQR)   |               |                   |              |         |
| >35-no. (%)              | 25.0(20.0-33.5) | 24.0(19.0-31.0)   | 33.0(23.8-55.5) | 0.005   |
| LDH-IU/L, median (IQR)   |               |                   |              |         |
| >25-no. (%)              | 51.36(32.6) | 37(30.1)          | 14(77.8)     | 0.000   |
| NT-proBNP-ng/L, median (IQR) |          |                   |              |         |
| >1800-no. (%)            | 290.0(150.8-819.0) | 260.0(124.0-512.0) | 2362.5(1707.6-2978.3) | 0.000   |
| Ground-glass opacity lesions on CT |          |                   |              |         |
| 1-2 lung lobes, no. (%)  | 88(62.4)     | 82(66.7)          | 6(33.3)      | 0.000   |
| ≥3 lung lobes, no. (%)   | 53(37.6)     | 41(33.3)          | 12(66.7)     | 0.000   |

P values denoted the comparison between Discharged and Death groups. IQR interquartile range, WBC white blood cell, RBC red blood cell, CRP C reaction protein, BUN blood urea nitrogen, AST aspartateaminotransferase, ALT alanineaminotransferase, LDH lactic dehydrogenase, TB total bilirubin, Hs-Tni hypersensitive troponin I, CK-MB creatinekinase-MB, CK creatine kinase, NT-proBNP N-terminal pro-brain natriuretic peptide, CT computed tomography.

Table 3 Complication and Treatment during hospitalizationin the Discharged and Death Groups
| Complication-no. (%) | Total (n=141) | Discharged (n=123) | Death (n=18) | P value |
|----------------------|---------------|--------------------|--------------|---------|
| Arrhythmia           | 39 (27.7)     | 32 (26.0)          | 7 (38.9)     | 0.391   |
| ARDS                 | 17 (12.1)     | 7 (5.7)            | 10 (55.6)    | 0.000   |
| Shock                | 8 (5.7)       | 0 (0)              | 8 (44.4)     | 0.000   |
| **Treatment-no. (%)**|               |                    |              |         |
| Antiviral therapy    | 131 (92.9)    | 116 (92.8)         | 15 (93.8)    | 1.000   |
| Oseltamivir          | 18 (12.8)     | 17 (13.8)          | 1 (5.6)      | 0.546   |
| Arbidol              | 129 (91.5)    | 113 (91.9)         | 16 (88.9)    | 1.000   |
| Oseltamivir+Arbidol  | 16 (11.3)     | 15 (12.2)          | 1 (5.6)      | 0.666   |
| Antibiotics          | 108 (76.6)    | 90 (73.2)          | 18 (100.0)   | 0.027   |
| Antifungal           | 6 (4.3)       | 3 (2.4)            | 3 (16.7)     | 0.028   |
| Glucocorticoid       | 29 (20.6)     | 16 (13.0)          | 13 (72.2)    | 0.000   |
| Immunoglobulin transfusion | 15 (10.6) | 8 (6.5)            | 7 (38.9)     | 0.000   |
| Blood transfusion    | 8 (5.7)       | 5 (4.1)            | 3 (16.7)     | 0.107   |
| NIV-no. (%)          | 15 (10.6)     | 4 (3.3)            | 11 (61.1)    | 0.000   |
| IMV-no. (%)          | 6 (4.3)       | 1 (0.8)            | 5 (27.8)     | 0.000   |

*P value: comparison between Discharged and Death groups. ARDS acute respiratory distress syndrome, NIV noninvasive ventilation, IMV invasive mechanical ventilation.*

**Table 4** Univariate and Multivariate Logistic Regression for Prediction of In-hospital Death
|                          | Univariate OR(95%CI) | P value | Multivariate OR(95%CI) | P value |
|--------------------------|---------------------|---------|-----------------------|---------|
| **Sex (Male)**           |                      |         |                       |         |
| **Sign**                 |                      |         |                       |         |
| Respiratory rate         | 2.6(1.0-7.3)         | 0.062   | 13.1(1.1-160.1)       | 0.044   |
| Temperature-°C            | 3.9(1.2-13.0)        | 0.026   | 80.5(4.6-1407.6)      | 0.003   |
| ≤37.3°C                  | 1(ref)              |         |                       |         |
| >37.3°C                  | 8.1(2.5-25.9)        | 0.000   | 70.1(4.6-1060.4)      | 0.002   |
| **SpO₂**                 |                      |         |                       |         |
| >90%                     | 1(ref)              |         |                       |         |
| ≤90%                     | 15.8(5.0-50.1)       | 0.000   |                       |         |
| **Comorbidity**          |                      |         |                       |         |
| (present vs. not present)| 6.4(2.3-18.3)        | 0.000   | 34.9(3.6-334.0)       | 0.002   |
| Central nerve system disorders|  |         |                       |         |
| Chronic kidney disease   | 34.9(3.6-334.0)      | 0.002   |                       |         |
| **Laboratory finding**   |                      |         |                       |         |
| WBC-×10⁹/L               | 1(ref)              |         | 9.0(2.9-28.1)         | 0.000   |
| ≤10.0                    |                      |         |                       |         |
| >10.0                    |                      |         |                       |         |
| Lymphocyte count-×10⁹/L  | 1(ref)              | 4.7(1.6-14.0) | 0.006   |
| >1.1                     |                      |         |                       |         |
| ≤1.1                     |                      |         |                       |         |
| Neutrophil count-×10⁹/L  | 1(ref)              | 5.2(1.8-14.5) | 0.002   |
| ≤6.3                     |                      |         |                       |         |
| >6.3                     |                      |         |                       |         |
| Platelet count-×10⁹/L    | 1(ref)              | 9.1(2.3-35.6) | 0.002   |
| >100                     |                      |         |                       |         |
| ≤100                     |                      |         |                       |         |
| WBC×10⁹/L                | 9.2(2.9-28.1)        | 0.000   |                       |         |
| ≤10.0                    |                      |         |                       |         |
| >10.0                    |                      |         |                       |         |
| Lymphocyte count-×10⁹/L  | 1(ref)              | 4.7(1.6-14.0) | 0.006   |
| >1.1                     |                      |         |                       |         |
| ≤1.1                     |                      |         |                       |         |
| Neutrophil count-×10⁹/L  | 1(ref)              | 5.2(1.8-14.5) | 0.002   |
| ≤6.3                     |                      |         |                       |         |
| >6.3                     |                      |         |                       |         |
| Platelet count-×10⁹/L    | 1(ref)              | 9.1(2.3-35.6) | 0.002   |
| >100                     |                      |         |                       |         |
| ≤100                     |                      |         |                       |         |
| Hemoglobin-g/L           | 1(ref)              | 2.7(0.8-8.5) | 0.102   |
| >110                     |                      |         |                       |         |
| ≤110                     |                      |         |                       |         |
| PCT-ng/L                 | 1(ref)              | 2.5(0.9-6.9) | 0.080   |
| ≤500                     |                      |         |                       |         |
| >500                     |                      |         |                       |         |
| D-dimer-ng/L             | 1(ref)              | 97.6(11.1-860.4) | 0.000   |
| ≤1.0                     |                      |         |                       |         |
| >1.0                     |                      |         |                       |         |
| Cr-μmol/L                | 1(ref)              | 23.2(3.0-180.0) | 0.003   |
| ≤97                      |                      |         |                       |         |
| >97                      |                      |         |                       |         |
| BUN-mmol/L               | 1(ref)              | 3.6(1.3-9.8) | 0.015   |
| ≤7.1                     |                      |         |                       |         |
| >7.1                     |                      |         |                       |         |
| LDH-IU/L                 | 1(ref)              | 5.0(1.8-14.4) | 0.003   |
| ≤250                     |                      |         |                       |         |
| >250                     |                      |         |                       |         |
| Hs-TnI-ng/L              | 1(ref)              | 8.1(2.5-26.4) | 0.000   |
| ≤26                      |                      |         |                       |         |
| >26                      |                      |         |                       |         |
| NT-proBNP-ng/L           | 1(ref)              | 15.2(4.8-47.7) | 0.000   |
| ≤1800                    |                      |         |                       |         |
| >1800                    | 37.4(10.6-131.2)     | 0.000   |                       |         |
| NT-proBNP-ng/L           | 1(ref)              | 273.5(14.7-5104.8) | 0.000   |
| ≤1800                    |                      |         |                       |         |
| >1800                    | 37.4(10.6-131.2)     | 0.000   |                       |         |
| Ground-glass opacity lesions on CT | |         |                       |         |
| 1-2 Lung lobes           | 1(ref)              | 4.0(1.4-11.4) | 0.010   |
| ≥3 Lung lobes            |                      |         |                       |         |

SpO₂ pulse oxygen saturation, WBC white blood cell, RBC red blood cell, PCT procalcitonin, Cr creatinine, BUN blood urea nitrogen, LDH lactic dehydrogenase, Hs-TnI hypersensitive troponin I, NT-proBNP N-terminal pro-brain natriuretic peptide, CT computed tomography, CI confidence interval.